New antiretroviral agents in clinical development

Research output: Contribution to journalArticle

Abstract

As we expand our understanding of the biology of the human immunodeficiency virus, we generate an increasing directory of potential antiretroviral therapies. Despite this increase, the number of promising new agents entering clinical trials is limited by unexpected toxicity, lower than anticipated activity, resistance, or problems with drug disposition or manufacture. In the past year, it seems that more antiretroviral agents have met with failure than with success. Nonetheless, the increasing sophistication of applied science in this field, and the continued availability of novel agents for clinical study, provide encouragement. Three major trends have emerged: 1) the continuing predominance of nucleoside analogues that inhibit the viral reverse transcriptase, despite their toxicities and limited clinical benefit; 2) the increasing importance of drug resistance in governing the use of available agents and in guiding the development of new classes of drugs; and 3) the accelerated licensure of promising new drugs for acquired immunodeficiency syndrome, exemplified by the approval of didanosine (dideoxyinosine) and zalcitabine (dideoxycytidine).

Original languageEnglish (US)
Pages (from-to)798-805
Number of pages8
JournalCurrent Opinion in Infectious Diseases
Volume5
Issue number6
StatePublished - 1992

Fingerprint

Anti-Retroviral Agents
Zalcitabine
Didanosine
Pharmaceutical Preparations
Directories
RNA-Directed DNA Polymerase
Licensure
Nucleosides
Drug Resistance
Acquired Immunodeficiency Syndrome
Clinical Trials
HIV
Therapeutics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology

Cite this

New antiretroviral agents in clinical development. / Flexner, Charles Williams.

In: Current Opinion in Infectious Diseases, Vol. 5, No. 6, 1992, p. 798-805.

Research output: Contribution to journalArticle

@article{6e1d7784b5004e14bfdce905ab7b6952,
title = "New antiretroviral agents in clinical development",
abstract = "As we expand our understanding of the biology of the human immunodeficiency virus, we generate an increasing directory of potential antiretroviral therapies. Despite this increase, the number of promising new agents entering clinical trials is limited by unexpected toxicity, lower than anticipated activity, resistance, or problems with drug disposition or manufacture. In the past year, it seems that more antiretroviral agents have met with failure than with success. Nonetheless, the increasing sophistication of applied science in this field, and the continued availability of novel agents for clinical study, provide encouragement. Three major trends have emerged: 1) the continuing predominance of nucleoside analogues that inhibit the viral reverse transcriptase, despite their toxicities and limited clinical benefit; 2) the increasing importance of drug resistance in governing the use of available agents and in guiding the development of new classes of drugs; and 3) the accelerated licensure of promising new drugs for acquired immunodeficiency syndrome, exemplified by the approval of didanosine (dideoxyinosine) and zalcitabine (dideoxycytidine).",
author = "Flexner, {Charles Williams}",
year = "1992",
language = "English (US)",
volume = "5",
pages = "798--805",
journal = "Current Opinion in Infectious Diseases",
issn = "0951-7375",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - New antiretroviral agents in clinical development

AU - Flexner, Charles Williams

PY - 1992

Y1 - 1992

N2 - As we expand our understanding of the biology of the human immunodeficiency virus, we generate an increasing directory of potential antiretroviral therapies. Despite this increase, the number of promising new agents entering clinical trials is limited by unexpected toxicity, lower than anticipated activity, resistance, or problems with drug disposition or manufacture. In the past year, it seems that more antiretroviral agents have met with failure than with success. Nonetheless, the increasing sophistication of applied science in this field, and the continued availability of novel agents for clinical study, provide encouragement. Three major trends have emerged: 1) the continuing predominance of nucleoside analogues that inhibit the viral reverse transcriptase, despite their toxicities and limited clinical benefit; 2) the increasing importance of drug resistance in governing the use of available agents and in guiding the development of new classes of drugs; and 3) the accelerated licensure of promising new drugs for acquired immunodeficiency syndrome, exemplified by the approval of didanosine (dideoxyinosine) and zalcitabine (dideoxycytidine).

AB - As we expand our understanding of the biology of the human immunodeficiency virus, we generate an increasing directory of potential antiretroviral therapies. Despite this increase, the number of promising new agents entering clinical trials is limited by unexpected toxicity, lower than anticipated activity, resistance, or problems with drug disposition or manufacture. In the past year, it seems that more antiretroviral agents have met with failure than with success. Nonetheless, the increasing sophistication of applied science in this field, and the continued availability of novel agents for clinical study, provide encouragement. Three major trends have emerged: 1) the continuing predominance of nucleoside analogues that inhibit the viral reverse transcriptase, despite their toxicities and limited clinical benefit; 2) the increasing importance of drug resistance in governing the use of available agents and in guiding the development of new classes of drugs; and 3) the accelerated licensure of promising new drugs for acquired immunodeficiency syndrome, exemplified by the approval of didanosine (dideoxyinosine) and zalcitabine (dideoxycytidine).

UR - http://www.scopus.com/inward/record.url?scp=0026473967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026473967&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0026473967

VL - 5

SP - 798

EP - 805

JO - Current Opinion in Infectious Diseases

JF - Current Opinion in Infectious Diseases

SN - 0951-7375

IS - 6

ER -